Osteoporosis Diagnosis and Management: DXA, FRAX, and Pharmacologic Therapy

Osteoporosis Diagnosis and Management: DXA, FRAX, and Pharmacologic Therapy

Category: EndocrinologyAuthor: gomdoriReading time: 15 min

Executive Summary

Osteoporosis is a silent skeletal disease — the first sign is often a low-trauma fracture at the hip, vertebra, or wrist, after which one-year mortality for hip fracture reaches 20–30%. Diagnosis rests on three parallel pillars: a DXA T-score ≤ −2.5 at the lumbar spine, femoral neck, or total hip; any fragility fracture in an adult ≥50 years regardless of BMD; or a FRAX 10-year major osteoporotic fracture risk ≥20% or hip fracture risk ≥3% in the osteopenic range. Management layers universal bone health (calcium 1000–1200 mg/day, vitamin D 800–2000 IU/day, weight-bearing exercise, fall prevention) onto pharmacotherapy stratified by fracture risk. Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) remain first-line; IV zoledronic acid 5 mg yearly rescues adherence and GI intolerance. Denosumab 60 mg SC every 6 months serves patients with eGFR <35 mL/min but carries an absolute requirement for antiresorptive follow-up if discontinued — rebound vertebral fractures occur within 7–18 months. For very high-risk patients (T-score ≤ −3.0, or ≤ −2.5 with recent fragility fracture), anabolic-first sequencing with romosozumab 210 mg SC monthly × 12 months, teriparatide 20 mcg SC daily, or abaloparatide 80 mcg SC daily — followed by bisphosphonate consolidation — outperforms antiresorptive-only therapy. Drug holidays apply only to bisphosphonates after 5 years oral or 3 years IV in low-to-moderate risk patients; denosumab and anabolics have no safe off-ramp.

≤ −2.5DXA T-score threshold
20% / 3%FRAX major / hip risk
40–70%Vertebral fracture risk reduction
20–30%1-year hip fracture mortality

S1. Pathophysiology & Fracture Epidemiology

Bone is not inert — it is a continuously remodeled tissue in which osteoclasts resorb packets of matrix and osteoblasts rebuild them on a 3–6 month cycle. Peak bone mass is reached in the third decade and declines thereafter, accelerating sharply in women during the first 5–7 years after menopause, when estrogen withdrawal unleashes RANKL-driven osteoclastogenesis. Trabecular bone (vertebrae, distal radius, femoral neck) loses up to 30% of mass in this window; cortical bone thins more gradually through the sixth through ninth decades. The net result is microarchitectural deterioration — perforated trabeculae, enlarged resorption cavities, and reduced cortical thickness — that predisposes to fracture at loads a healthy skeleton would tolerate easily.

The epidemiologic burden is immense: in the United States alone, ~2 million fragility fractures occur annually, with direct costs exceeding $20 billion. Lifetime risk is ~50% in women and ~20% in men after age 50. The hip fracture is the most feared event — 20–30% one-year mortality, with half of survivors never regaining prior ambulatory independence. Vertebral fractures, often clinically silent (two-thirds are radiographic incidental findings), signal a five-fold increase in subsequent vertebral fracture risk and doubled hip fracture risk. The imperative is clear: identify risk before the first fracture, because secondary prevention after a sentinel event still leaves a substantial residual morbidity curve.

Primary osteoporosis encompasses postmenopausal (Type I, estrogen-deficient, trabecular-dominant, vertebral fractures) and senile (Type II, age-related, cortical + trabecular, hip fractures in both sexes). Secondary osteoporosis accounts for 30% of postmenopausal and 50% of male cases: glucocorticoids (≥5 mg prednisone daily ≥3 months), hypogonadism (aromatase inhibitors, androgen deprivation), hyperthyroidism, hyperparathyroidism, celiac disease, CKD (mineral bone disorder), multiple myeloma, anti-epileptic drugs (phenytoin, phenobarbital), SSRIs, PPIs (contested), and alcohol use disorder. Every newly diagnosed patient — especially men and premenopausal women — warrants a secondary workup: CBC, CMP, 25-OH vitamin D, TSH, PTH, 24-hour urinary calcium, tissue transglutaminase IgA, testosterone (men), and serum/urine protein electrophoresis when clinically indicated.

Postmenopausal Bone Loss — Estrogen / RANKL / OPG AxisDiagram showing how the fall in estrogen after menopause raises RANKL and lowers OPG, tipping the RANKL to OPG ratio toward osteoclast differentiation, accelerated bone resorption, and net bone loss with fracture risk. Antiresorptive drugs act at the RANKL step.Postmenopausal Bone Loss — Estrogen / RANKL / OPG AxisEstrogen withdrawal shifts the RANKL:OPG ratio toward net bone resorptionMenopause / AgingOvarian estrogen ↓↓(also glucocorticoids, hyperthyroid)Osteoblast / Stromal cellRANKL ↑ (decoy OPG ↓)Low estrogen removes RANKL restraintOsteoclastDifferentiation & survival ↑RANK receptor activationRANKL : OPG ratio ↑Central switch determining resorption rateResorption > FormationUncoupled remodelingTrabecular loss up to 30%Microarchitecture → fragility fractureDrug targets on this axisDenosumab → blocks RANKL directlyBisphosphonates → osteoclast apoptosisClinical correlatesFastest loss: first 5–7 yr post-menopauseCTX / P1NP turnover markers riseAntiresorptives ↓ markersStopping denosumab reverses RANKL blockade → rebound resorption and vertebral fractures within 7–18 months
Osteoporosis Diagnosis and Management — Hormonal Axis

S2. Screening, DXA Interpretation & FRAX

USPSTF and NOF/BHOF converge on universal screening: all women ≥65 years and all men ≥70 years. Earlier screening applies when risk is elevated — postmenopausal women <65 or men 50–69 with FRAX ≥9.3% for major osteoporotic fracture, or with clinical risk factors: prior fragility fracture, long-term glucocorticoid use, parental hip fracture, low body weight (<58 kg or BMI <20), current smoking, alcohol ≥3 units/day, rheumatoid arthritis, or known secondary causes. Any adult ≥50 years with a fragility fracture — regardless of screening history — earns a DXA, because the fracture itself defines clinical osteoporosis and modifies therapy selection.

DXA Interpretation

T-score compares the patient’s BMD to a young-adult reference (sex-matched, peak bone mass). The WHO definitions apply at the lumbar spine (L1–L4), femoral neck, and total hip — always use the lowest of these three sites. Forearm (33% radius) DXA is reserved for patients who cannot undergo spine/hip DXA (hardware, severe scoliosis, obesity >300 lb), and for hyperparathyroidism surveillance.

CategoryT-scoreZ-score interpretationClinical action
Normal≥ −1.0Not used for diagnosis if age >50Lifestyle measures; rescreen q5–10y
Osteopenia (low bone mass)−1.0 to −2.5—Calculate FRAX; treat if MOF ≥20% or hip ≥3%
Osteoporosis≤ −2.5—Pharmacotherapy indicated
Severe (established) osteoporosis≤ −2.5 and fragility fracture—Consider anabolic-first strategy
Z-score ≤ −2.0 (premenopausal / men <50)Use Z not T“Below expected for age”Investigate secondary causes aggressively

Trabecular Bone Score (TBS) is a texture analysis of the lumbar spine DXA image that estimates bone microarchitecture independent of BMD. A TBS <1.23 is “degraded,” 1.23–1.31 “partially degraded,” >1.31 “normal” — and adjusts FRAX output upward when degraded, capturing risk that BMD alone misses (notably in diabetes, where BMD is paradoxically normal but fracture risk is elevated). Vertebral Fracture Assessment (VFA) is a lateral spine image acquired on the DXA scanner to detect occult vertebral fractures; order it in any patient ≥70 with T-score ≤ −1.0, height loss >4 cm, historical height loss >2 cm over documented prior height, or chronic glucocorticoid use. One-third of osteoporosis reclassifications upward come from a newly detected silent vertebral fracture on VFA.

FRAX Calculator

FRAX is the WHO’s country-specific 10-year fracture risk calculator (fraxplus.org), incorporating age, sex, BMI, prior fracture, parental hip fracture history, smoking, glucocorticoids, rheumatoid arthritis, secondary osteoporosis, alcohol, and optionally femoral neck BMD. Output is 10-year probability of major osteoporotic fracture (MOF: spine, hip, wrist, humerus) and hip fracture alone. US thresholds for pharmacologic intervention in osteopenic patients: MOF ≥20% or hip ≥3%. Limitations: FRAX underestimates risk when the patient has had multiple fractures (only “any prior fracture” yes/no), very high-dose glucocorticoids, diabetes, or severe spinal BMD loss disproportionate to hip; adjust upward by ~30% for prednisone ≥7.5 mg/day, and consider TBS-adjusted FRAX for diabetics.

When to Order VFA

Lateral spine imaging (VFA or plain films) is indicated whenever a vertebral fracture would change management: women ≥70 or men ≥80 with T-score ≤ −1.0; height loss >4 cm from peak or >2 cm measured; chronic glucocorticoid ≥5 mg/day ≥3 months; or unexplained back pain in an osteopenic/osteoporotic patient. A single Grade 2 (moderate, 25–40% vertebral height loss) or Grade 3 (severe, >40%) fracture reclassifies the patient as severe osteoporosis and triggers anabolic consideration.

Secondary workup labs (run in every newly diagnosed patient, especially men and premenopausal women): CBC, CMP (calcium, phosphorus, creatinine, albumin, alkaline phosphatase), 25-hydroxyvitamin D (target >30 ng/mL), intact PTH, TSH, 24-hour urine calcium (to screen for hypercalciuria and malabsorption), tissue transglutaminase IgA (celiac), and serum/urine protein electrophoresis in patients >50 with unexplained bone loss or anemia. In men, add total and free testosterone. Abnormal calcium prompts PTH interpretation (primary vs secondary hyperparathyroidism), abnormal alkaline phosphatase raises concern for Paget’s or osteomalacia, and low 24-hour urine calcium (<50 mg/day) with elevated PTH suggests vitamin D deficiency or malabsorption rather than primary hyperparathyroidism.

S3. Pharmacologic Therapy: Antiresorptives & Anabolics

All patients receive the universal bone health foundation: calcium 1000–1200 mg/day (diet preferred; supplement only the shortfall, since supplemental calcium >1000 mg/day may raise CV risk), vitamin D 800–2000 IU/day (higher for malabsorption, target 25-OH vitamin D ≥30 ng/mL), weight-bearing and resistance exercise 30 minutes ≥3 days/week, fall risk mitigation (home safety evaluation, vision correction, psychotropic deprescribing), smoking cessation, and alcohol moderation (<3 units/day). Layered on top is pharmacotherapy stratified by fracture risk.

Antiresorptive Agents (First-line for Most Patients)

Drug (brand)Class / MoADose & routeKey cautions
Alendronate (Fosamax)Oral BP — inhibits farnesyl pyrophosphate synthase70 mg PO weekly on empty stomach, 30 min before food, uprighteGFR <30 avoid; GI intolerance; osteonecrosis of jaw (ONJ) <0.1%; atypical femur fracture (AFF) <0.1%
Risedronate (Actonel)Oral BP35 mg PO weekly or 150 mg monthlyDelayed-release form allows post-meal dosing; same cautions as alendronate
Ibandronate (Boniva)Oral/IV BP150 mg PO monthly or 3 mg IV q3 monthsNo hip fracture benefit demonstrated; second-line only
Zoledronic acid (Reclast)IV BP5 mg IV yearly (osteoporosis) or q2 years (osteopenia)eGFR <35 avoid; pretreat with acetaminophen for acute-phase reaction (flu-like, 30% with first dose); adequate hydration
Denosumab (Prolia)RANKL monoclonal antibody — blocks osteoclast differentiation60 mg SC every 6 monthseGFR-independent (use in CKD); hypocalcemia risk (correct vitamin D and calcium before first dose); no drug holiday — rebound vertebral fractures if stopped without antiresorptive transition; ONJ and AFF risks
Raloxifene (Evista)SERM — estrogen agonist on bone, antagonist on breast60 mg PO dailyVTE risk (contraindicated in prior VTE); vertebral-only efficacy (no hip benefit); reduces invasive breast cancer risk — niche for postmenopausal women with breast cancer risk
Estrogen (conjugated or estradiol)HRTLowest effective dose for menopausal symptomsReserve for women with vasomotor symptoms; do not prescribe solely for osteoporosis; VTE, CV, and breast cancer risk per WHI data

Anabolic Agents (Very High-Risk or Treatment-Failure Patients)

Drug (brand)Class / MoADose & routeKey cautions
Teriparatide (Forteo)Recombinant PTH 1-34 — intermittent PTH stimulates osteoblasts20 mcg SC daily × 24 months (lifetime)Black box: osteosarcoma (rodent data, not replicated in humans); avoid in prior skeletal radiation, Paget’s, hypercalcemia, open epiphyses; refrigerated pen
Abaloparatide (Tymlos)PTHrP analog80 mcg SC daily × 24 months (lifetime)Same class warnings as teriparatide; slightly less hypercalcemia than teriparatide
Romosozumab (Evenity)Anti-sclerostin monoclonal antibody — uncouples bone formation from resorption210 mg SC monthly × 12 months (two 105 mg injections at separate sites)Black box: MI, stroke, CV death — do not initiate within 12 months of MI/stroke; hypocalcemia; follow immediately with antiresorptive (bisphosphonate or denosumab) to preserve gains

Efficacy benchmarks (vertebral fracture risk reduction vs placebo): alendronate 45–50%, zoledronic acid 70%, denosumab 68%, teriparatide 65%, abaloparatide 86% (ACTIVE trial), romosozumab 73% at 12 months (FRAME). Hip fracture risk reduction: alendronate 53%, zoledronic acid 41%, denosumab 40%, romosozumab 38% when followed by alendronate (ARCH). Non-vertebral fracture reduction is more modest (~20% for oral BP) and drives much of the number-needed-to-treat calculus.

Denosumab Discontinuation — Critical Rebound Risk

Stopping denosumab without transition causes bone turnover markers to rebound above baseline within 3–6 months, and multiple vertebral fractures within 7–18 months — documented in the FREEDOM extension, with some patients sustaining 4–8 new vertebral fractures in a single event. Every denosumab prescription carries an implicit commitment: if the drug is ever stopped (patient preference, cost, dental procedure), transition 6 months after the last dose to oral alendronate 70 mg weekly × 1–2 years or a single zoledronic acid 5 mg IV infusion. Do not simply stop.

S4. Sequencing, Drug Holidays & Special Populations

Treatment Sequencing by Risk Tier

The 2020 AACE and 2022 Endocrine Society guidelines stratify postmenopausal women into moderate risk (osteopenia with elevated FRAX, or T-score −2.5 to −3.0 without fracture) and very high risk (T-score ≤ −2.5 with fragility fracture, T-score ≤ −3.0, multiple vertebral fractures, or FRAX MOF >30% / hip >4.5%). Moderate risk begins with antiresorptives (oral BP first-line, IV BP or denosumab if intolerant or CKD). Very high risk begins with anabolic-first sequencing — romosozumab × 12 months or teriparatide/abaloparatide × 18–24 months — followed by antiresorptive consolidation. The rationale: anabolic agents build new bone rapidly, but without subsequent antiresorptive, gains regress; starting with antiresorptive blunts the subsequent response to anabolic. The ARCH trial demonstrated that romosozumab → alendronate reduced hip fracture by 38% vs alendronate alone; the VERO trial showed teriparatide outperformed risedronate in vertebral fracture prevention.

Risk tierFirst-line agentSequence afterDuration
Moderate (T −2.5 to −3.0, no fracture)Alendronate 70 mg weekly or zoledronic acid 5 mg IV yearlyDrug holiday after 5 y PO / 3 y IV if low-risk5 y oral / 3 y IV then reassess
High (T ≤ −3.0 or recent fracture)Zoledronic acid 5 mg IV yearly or denosumab 60 mg q6moContinue indefinitely; no holiday for denosumabReassess q3–5 y
Very high (T ≤ −2.5 + fracture, multiple fractures, FRAX hip >4.5%)Romosozumab 210 mg monthly × 12 mo or teriparatide/abaloparatide × 18–24 moTransition to alendronate or denosumabAnabolic 12–24 mo → antiresorptive ≥3–5 y

Bisphosphonate Drug Holiday

Bisphosphonates bind hydroxyapatite and persist in bone for years — the rationale for a drug holiday after 5 years of oral alendronate or 3 years of IV zoledronic acid in patients who have become low-to-moderate risk. Reassess at the holiday decision point: DXA (looking for stability or <3–5% loss), any interval fracture, change in FRAX. Pause for 2–3 years with annual monitoring in patients with hip T-score > −2.5 and no interval fracture. Do not offer a drug holiday to patients with T-score ≤ −2.5 at hip, recent fracture, continued glucocorticoid exposure, or denosumab therapy. The holiday is a bisphosphonate-specific phenomenon; other agents require continuous therapy or structured sequencing.

Glucocorticoid-Induced Osteoporosis (GIOP)

Bone loss begins within weeks of initiating glucocorticoids ≥2.5 mg prednisone daily, with the greatest loss in the first 3–6 months. Screen DXA at baseline for any patient starting ≥5 mg prednisone expected to continue ≥3 months, and treat aggressively: the ACR 2017 guideline recommends alendronate, risedronate, or zoledronic acid as first-line, with teriparatide or denosumab for high-risk patients or those with contraindications to BP. Add calcium 1200 mg/day and vitamin D 800–1000 IU/day universally. FRAX underestimates GIOP risk — adjust upward by 15% for prednisone ≥7.5 mg/day, or use GIOP-specific calculators.

Chronic Kidney Disease

eGFR <35 mL/min contraindicates bisphosphonates (both oral and IV) due to unpredictable pharmacokinetics and nephrotoxicity risk. Denosumab is eGFR-independent but requires careful calcium and vitamin D repletion before dosing (hypocalcemia risk ~13% in eGFR <30). Teriparatide/abaloparatide are usable at all eGFR. In stage 5 CKD or dialysis, differentiate osteoporosis from renal osteodystrophy (CKD-MBD) with PTH, phosphate, and in some cases bone biopsy — treatment differs fundamentally (phosphate binders, cinacalcet, active vitamin D analogs).

Men with Osteoporosis

Men account for 20–30% of hip fractures but are screened and treated far less. Screen men ≥70, and men 50–69 with clinical risk factors. Secondary workup is mandatory — 50% of men have an identifiable cause (hypogonadism, glucocorticoids, alcohol, celiac, hyperparathyroidism). Add total testosterone, free testosterone or SHBG, and consider prolactin/LH when hypogonadism is suspected. Treatment agents are similar to women: alendronate, risedronate, zoledronic acid, denosumab, teriparatide, and abaloparatide all have male-specific approval. Androgen replacement is considered for hypogonadal men with symptomatic deficiency but is not a substitute for osteoporosis-specific therapy.

Premenopausal Women

Low BMD in premenopausal women is usually secondary — amenorrhea (hypothalamic, athletic triad, POI), glucocorticoids, celiac, eating disorders, CKD. Address the underlying cause first. Bisphosphonates are teratogenic (FDA category C, persist in skeleton) — avoid in women planning pregnancy. Teriparatide and denosumab are also contraindicated in pregnancy. For severe cases with fragility fracture, treatment must be individualized with endocrinology/rheumatology input, often deferring pharmacotherapy until childbearing is complete unless fractures are recurrent.

Red Flag: Dental Procedures on Antiresorptives

Osteonecrosis of the jaw (ONJ) risk is very low (0.01–0.1% for osteoporosis doses of BP/denosumab, vs 1–10% in oncology doses used for skeletal-related events). Complete dental work — extractions, implants, periodontal surgery — before starting therapy when feasible. For patients on oral BP <4 years with no risk factors, routine dental procedures proceed without drug interruption. For longer courses, IV BP, or denosumab, consult oral surgery. Do not discontinue therapy unilaterally for routine cleanings or fillings.

S5. Monitoring, Adherence & Referral

Repeat DXA at 1–2 years after starting therapy in most patients, then q2–3 years when stable. Same facility, same machine — inter-device BMD differences can reach 5–10%, approaching the least significant change (LSC ~3–5%). Interpret against LSC: a change within ±LSC is stable, not “worsening” or “improving.” In patients on stable long-term therapy with no fractures, DXA can be extended to q3–5 years. On anabolic agents, BMD is expected to rise substantially — teriparatide/abaloparatide deliver +8–12% at spine and +3–5% at hip over 18–24 months; romosozumab delivers +13% spine and +6% hip at 12 months.

Bone turnover markers (BTM) — serum CTX (resorption) and P1NP (formation) — offer an early response signal (3–6 months) before BMD changes are detectable (12+ months). On bisphosphonates, CTX typically drops ≥30% and P1NP ≥25%; on denosumab, CTX suppression is deeper and more uniform; on anabolic therapy, P1NP rises ≥10 ng/mL above baseline within 3 months (a good early indicator of response). BTM are most useful when adherence is uncertain or when considering treatment failure. Do not use BTM as the sole monitoring tool — combine with DXA and clinical outcome (fracture, height).

Adherence is the single greatest determinant of real-world effectiveness. Oral bisphosphonate persistence at 1 year is ~50% and at 2 years ~35%, driven by GI symptoms, pill burden, and administration complexity (empty stomach, upright, wait 30 minutes). Switch to monthly oral risedronate, quarterly IV ibandronate, or — ideally — annual IV zoledronic acid or semi-annual denosumab for any patient flagging on adherence. Document the empty-stomach, water-only, upright-for-30-min instructions in each oral BP prescription.

When to Refer to Endocrinology or Metabolic Bone Specialist

Refer when: (1) treatment failure — interval fracture on therapy, BMD loss >LSC despite adherence; (2) secondary osteoporosis workup is abnormal (hypercalcemia, elevated PTH, low testosterone, positive celiac serology); (3) renal osteodystrophy or CKD-MBD is suspected; (4) unusual presentation — osteoporosis in a child, young adult, premenopausal woman without obvious cause, or atypical fractures (multiple ribs, bilateral femoral shaft); (5) complex sequencing decisions — denosumab discontinuation strategy, anabolic-to-antiresorptive transition, osteonecrosis of jaw; (6) glucocorticoid-dependent patient with ongoing high-dose exposure. Every fragility fracture in a patient ≥50 warrants at minimum a Fracture Liaison Service referral for systematic post-fracture care.

Long-term surveillance also captures medication-specific adverse events. Atypical femur fractures (subtrochanteric or diaphyseal, often bilateral) present as prodromal thigh pain — get bilateral femur imaging in any long-term BP or denosumab patient with new thigh pain. Osteonecrosis of the jaw presents as non-healing extraction site or exposed bone >8 weeks after a dental procedure — exam the oral cavity at each visit. Musculoskeletal pain is common in the first month of BP therapy; severe diffuse bone/joint pain warrants drug discontinuation.

S6. Practice Insights

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)In routine endocrinology continuity and post-fracture orthogeriatric practice, the lessons that most reshape the preferred approach to osteoporosis center on three paradigm shifts: AACE 2020 very-high-risk stratification driving anabolic-first therapy (romosozumab, teriparatide, abaloparatide), the denosumab discontinuation pitfall that produces rebound vertebral fractures, and structured fall prevention as a core component of osteoporosis management rather than a separate problem. The four observations below outline how each is navigated at the bedside.

What the Guideline Misses

The AACE 2020 guideline introduced “very high risk” as a distinct category requiring anabolic-first therapy (romosozumab, teriparatide, or abaloparatide) rather than bisphosphonate-first, but in routine practice most very-high-risk patients are still started on alendronate as the default. The ARCH trial (romosozumab vs alendronate) and VERO trial (teriparatide vs risedronate) demonstrated substantial fracture reduction with anabolic-first in this group. In experienced hands every very-high-risk patient (recent fracture <12 months, fractures on therapy, multiple fractures, T-score <-3.0, hip fracture) is offered romosozumab or teriparatide as first-line, with bisphosphonate or denosumab reserved for the sequencing phase after the 12-24 month anabolic course completes.

Patterns That Recur

The most consequential treatment harm in this area is denosumab discontinuation without bisphosphonate transition. Stopping denosumab produces rapid BMD loss and rebound multiple vertebral fractures within 6-18 months — a phenomenon described in multiple case series and now well-recognized but routinely overlooked. In experienced hands the denosumab decision is framed as a lifetime commitment from the start, and any patient considering discontinuation gets transitioned to oral alendronate 70 mg weekly or zoledronic acid 5 mg IV starting at the 6-month mark after the last denosumab dose. The transition prevents the rebound phenomenon and preserves the BMD gains.

A Practical Bedside Heuristic

Structured fall prevention belongs in every osteoporosis visit rather than in a separate referral. Fall prevention reduces fracture incidence more reliably than incremental BMD improvement in patients with established osteoporosis. A complete visit includes a formal Timed Up and Go test (>13.5 seconds is high fall risk), home hazard assessment (loose rugs, poor lighting, bathroom safety), medication review (sedatives, anticholinergics, antihypertensives causing orthostasis), vitamin D level optimization to ≥30 ng/mL, and grip strength check. Pharmacotherapy without fall prevention is incomplete care for osteoporosis.

What Experienced Practice Now Does Differently

The diagnostic conversation about secondary causes of osteoporosis now extends to every newly diagnosed patient, even those with a classic post-menopausal presentation. Approximately 20-30 percent of osteoporosis patients have an identifiable secondary cause that changes management: primary hyperparathyroidism, hyperthyroidism, hypercortisolism, vitamin D deficiency, multiple myeloma, celiac disease, hypogonadism, or medication-induced (glucocorticoids, AED, PPI, SSRI). A standard secondary workup includes CBC, CMP, TSH, 25-OH vitamin D, PTH, 24-hr urinary calcium, SPEP/UPEP/sFLC in age >50, and morning testosterone in men. Treating osteoporosis without addressing the underlying cause leaves substantial benefit unrealized.

Osteoporosis Therapy Map AACE 2020 very-high-risk pathway with romosozumab or teriparatide first-line plus denosumab-to-bisphosphonate transition and drug holiday timing Risk stratification × anabolic-first for very-high-risk × denosumab pitfall AACE 2020 risk stratification — paradigm shift from “T-score alone”: HIGH RISK: T-score <-2.5 OR FRAX hip ≥3% OR FRAX major ≥20% OR prior osteoporotic fracture VERY HIGH RISK: + recent fracture <12mo, fractures on osteoporosis therapy, multiple fractures, T-score <-3.0, fall risk, or pelvic/hip fracture Very-high-risk → anabolic-first; not bisphosphonate VERY HIGH RISK Anabolic-first paradigm First-line options: Romosozumab 210mg SC monthly × 12 Teriparatide 20mcg SC daily × 24mo Abaloparatide 80mcg SC daily × 18mo THEN bisphosphonate or denosumab Maintain BMD gains HIGH RISK Standard bisphosphonate First-line: Alendronate 70mg PO weekly OR zoledronic acid 5mg IV/yr Alternative: Denosumab 60mg SC q6mo CKD-friendly; do NOT discontinue Drug holiday (BP only) After 5 yr oral OR 3 yr IV Criteria for holiday: • Mild-moderate risk • No interim fractures • T-score improvement NEVER drug holiday: Denosumab (rebound risk) ⚠ DENOSUMAB DISCONTINUATION PITFALL Stopping denosumab causes rapid BMD loss + rebound vertebral fractures within 6-18 months If discontinuing: TRANSITION to oral bisphosphonate (alendronate 70mg/wk) OR zoledronic acid IV starting 6mo after last denosumab dose A practical rule: confirm patient understands “lifetime commitment” before starting denosumab — discontinuation is a clinical event, not a routine taper gomdori osteoporosis therapy map

An Illustrative Case: Anabolic-First in Very-High-Risk Disease

A woman in her early 70s presented after a hip fracture with subsequent T-score of -3.4 at femoral neck and three prevalent vertebral compression fractures on imaging. She met AACE very-high-risk criteria on multiple axes. The covering team started alendronate 70 mg weekly per institutional default and counseled “lifestyle plus calcium and vitamin D.” Within 14 months she sustained a second vertebral compression fracture despite reported alendronate adherence.

She was switched to romosozumab 210 mg SC monthly for 12 months, with planned transition to denosumab afterward. DXA at 12 months showed +14% BMD improvement at spine and +6% at hip, with no new fractures. The romosozumab course was followed by denosumab 60 mg SC every 6 months as the sequencing phase. At 24 months total follow-up she had had no additional fractures and her BMD had continued to improve.

What clinicians took from this case is that the historical “bisphosphonate-first regardless of risk” approach systematically undertreats the very-high-risk patient. The anabolic-first paradigm in this subgroup produces substantial absolute fracture reduction that bisphosphonate-first cannot match. Romosozumab and teriparatide should be the first-line choice in very-high-risk patients, not the salvage option after bisphosphonate failure.

Takeaway: Romosozumab, teriparatide, or abaloparatide as first-line in AACE very-high-risk osteoporosis (recent fracture, multi-fracture, T-score <-3.0, fracture on therapy). Bisphosphonate-first systematically undertreats this group; ARCH and VERO trials support anabolic-first.

Four Deviations From the Standard Protocol Worth Weighing

  1. Anabolic-first (romosozumab/teriparatide/abaloparatide) for AACE very-high-risk patients, NOT bisphosphonate-first. ARCH/VERO trials demonstrate substantial fracture reduction. Bisphosphonate or denosumab reserved for sequencing phase after 12-24 month anabolic course.
  2. Denosumab is lifetime commitment: discontinuation requires bisphosphonate bridge (alendronate 70mg weekly OR zoledronic acid IV) starting 6 months after last denosumab dose to prevent rebound vertebral fractures within 6-18 months.
  3. Structured fall prevention integrated into every osteoporosis visit: Timed Up and Go >13.5 sec, home hazard assessment, medication review, vitamin D to ≥30 ng/mL, grip strength. Pharmacotherapy without fall prevention is incomplete care.
  4. Secondary cause workup at every new diagnosis: CBC, CMP, TSH, 25-OH vitamin D, PTH, 24-hr urinary calcium, SPEP/UPEP/sFLC age >50, morning testosterone in men. ~20-30% have identifiable secondary cause changing management.

S7. Pearls, Pitfalls & FAQ

Pearl: Any Fragility Fracture = Osteoporosis

A hip, vertebral, pelvic, distal radius, or humeral fracture in an adult ≥50 years from a fall from standing height or less defines clinical osteoporosis, regardless of DXA T-score. Do not be anchored by a normal or osteopenic T-score after a fragility fracture — the fracture itself justifies pharmacotherapy, and DXA simply informs sequencing (anabolic-first if T ≤ −2.5, antiresorptive if higher). Fracture Liaison Services reduce 2-year refracture risk by 30–40% by systematically capturing these patients from orthopedics and ED visits.

Pitfall: Stopping Denosumab Without Transition

Denosumab has a short half-life (~26 days) and a profound rebound — RANKL-driven osteoclastogenesis is suppressed, then released within months, producing rapid multiple vertebral fractures. Never stop denosumab because of cost, dental work, or patient preference without a transition plan. Six months after the last denosumab dose, administer oral alendronate 70 mg weekly × 12–24 months, or a single IV zoledronic acid 5 mg infusion. This discipline is the single most important pharmacovigilance lesson in modern osteoporosis care.

Pearl: Diabetes Inflates Fracture Risk Beyond BMD

Type 2 diabetes patients fracture at higher rates than BMD predicts — BMD is paradoxically normal or elevated due to increased adiposity and AGE cross-linking, but bone quality is degraded. Use TBS-adjusted FRAX or simply adjust FRAX output upward; treat at lower T-score thresholds. The same applies to chronic inflammatory disease (RA, IBD) and hyperparathyroidism — fracture risk exceeds what BMD alone suggests.

Pitfall: Calcium Supplementation Without Dietary Assessment

Reflexive 1200 mg elemental calcium supplementation causes constipation, kidney stones, and possibly CV events. Assess dietary calcium first — three servings of dairy (300 mg each) plus fortified foods often meets the goal. Supplement only the shortfall (typically 500–600 mg if dietary intake is 600 mg). Keep single supplement doses ≤500 mg (absorption saturates) and take with meals. Vitamin D 800–2000 IU/day is nearly always needed to achieve 25-OH D >30 ng/mL.

Frequently Asked Questions

When do I screen for osteoporosis with DXA?
All women ≥65 years and men ≥70 years regardless of risk factors. Screen earlier (postmenopausal women <65, men 50–69) when FRAX-calculated 10-year major osteoporotic fracture risk is ≥9.3%, or when clinical risk factors are present: prior fragility fracture, glucocorticoid use >5 mg prednisone daily >3 months, parental hip fracture, low body weight (<58 kg), current smoking, alcohol ≥3 units/day, rheumatoid arthritis, or secondary causes (hypogonadism, hyperthyroidism, celiac disease). Any adult ≥50 with a fragility fracture warrants DXA regardless of prior screening.
How do I choose between bisphosphonates, denosumab, and romosozumab?
First-line is oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for most postmenopausal women and men. Switch to IV zoledronic acid 5 mg yearly for GI intolerance, adherence concerns, or malabsorption. Use denosumab 60 mg SC every 6 months when eGFR <35 mL/min (bisphosphonates contraindicated) or when oral/IV bisphosphonates fail; counsel carefully on the rebound risk if stopped without transition. Reserve romosozumab 210 mg SC monthly × 12 months (followed by antiresorptive) for very high-risk patients (T-score ≤−2.5 with prior fracture or T-score ≤−3.0) without recent MI/stroke (boxed CV warning). Teriparatide/abaloparatide are alternatives for very high-risk patients or those intolerant to other therapies.
Is a drug holiday safe for every osteoporosis medication?
No — drug holidays are specific to bisphosphonates. After 5 years of oral alendronate or 3 years of IV zoledronic acid, reassess: low-risk patients (T-score >−2.5, no recent fracture) can pause therapy for 2–3 years with annual DXA and fracture assessment. Denosumab has NO drug holiday — stopping causes a rapid rebound in bone turnover with a surge in vertebral fractures within 7–18 months. When discontinuing denosumab, transition immediately to a bisphosphonate (oral alendronate for 1–2 years or a single zoledronic acid infusion 6 months after the last denosumab dose). Anabolic agents (teriparatide, abaloparatide, romosozumab) similarly require antiresorptive follow-up to lock in gains.

Author: gomdori · Category: Endocrinology · Reviewed: 2026

This content is educational and does not replace individualized clinical judgment. Always integrate patient-specific factors and current institutional protocols.

Leave a Reply

Your email address will not be published. Required fields are marked *